IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis.
atopic dermatitis
interleukins
pruritus
psoriasis
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
04
2020
accepted:
15
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Pruritus is the most common symptom in patients with skin disease. Psoriasis and atopic dermatitis are clinically distinct inflammatory diseases. Interleukins are cytokines which play key roles in inflammatory signaling pathways. Cross-sectional study was conducted among patients with psoriasis and atopic dermatitis: 59 psoriatic patients, 56 AD patients, and 49 matched healthy controls. Interleukins 4, 13, 31, 33 serum levels were assayed by ELISA and results were compared using SPSS. Itch severity and disease severity were measured and correlation with interleukin levels was determined using SPSS. The serum levels of IL-4, -13, -31, -33 were elevated in atopic dermatitis patients compared to controls. Itch and disease severity were not correlated with elevated serum levels of these interleukins. In psoriasis, the levels of IL-4 and -31 were elevated compared to controls, whereas the levels of IL-13 and -33 were lower than controls. The levels of measured interleukins in psoriasis did not correlate with itch and disease severity. IL-31 is the key mediator for pruritus in both AD and Ps patients. IL-4/31 axis and IL-33/13 axis play distinct roles in the pathogenesis of Atopic dermatitis and Psoriasis. Interleukin serum levels were not correlated with itch and disease severity in both conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Pruritus is the most common symptom in patients with skin disease. Psoriasis and atopic dermatitis are clinically distinct inflammatory diseases. Interleukins are cytokines which play key roles in inflammatory signaling pathways.
MATERIALS AND METHODS
METHODS
Cross-sectional study was conducted among patients with psoriasis and atopic dermatitis: 59 psoriatic patients, 56 AD patients, and 49 matched healthy controls. Interleukins 4, 13, 31, 33 serum levels were assayed by ELISA and results were compared using SPSS. Itch severity and disease severity were measured and correlation with interleukin levels was determined using SPSS.
RESULTS
RESULTS
The serum levels of IL-4, -13, -31, -33 were elevated in atopic dermatitis patients compared to controls. Itch and disease severity were not correlated with elevated serum levels of these interleukins. In psoriasis, the levels of IL-4 and -31 were elevated compared to controls, whereas the levels of IL-13 and -33 were lower than controls. The levels of measured interleukins in psoriasis did not correlate with itch and disease severity.
CONCLUSION
CONCLUSIONS
IL-31 is the key mediator for pruritus in both AD and Ps patients. IL-4/31 axis and IL-33/13 axis play distinct roles in the pathogenesis of Atopic dermatitis and Psoriasis. Interleukin serum levels were not correlated with itch and disease severity in both conditions.
Identifiants
pubmed: 32606880
doi: 10.2147/CCID.S257647
pii: 257647
pmc: PMC7310969
doi:
Types de publication
Journal Article
Langues
eng
Pagination
419-424Informations de copyright
© 2020 Bodoor et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Br J Dermatol. 2018 Jan;178(1):34-60
pubmed: 29357600
J Allergy Clin Immunol. 2013 Aug;132(2):446-54.e5
pubmed: 23694808
J Invest Dermatol. 2018 Jun;138(6):1311-1317
pubmed: 29317264
Int J Mol Sci. 2019 Aug 20;20(16):
pubmed: 31434203
Allergol Immunopathol (Madr). 2018 Jul - Aug;46(4):322-325
pubmed: 29555105
J Allergy Clin Immunol. 2018 Nov;142(5):1375-1390
pubmed: 30409247
Int J Mol Sci. 2019 May 08;20(9):
pubmed: 31072011
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Feb 28;43(2):124-130
pubmed: 29559593
J Allergy Clin Immunol. 2006 Oct;118(4):930-7
pubmed: 17030248
Acta Derm Venereol. 2019 Feb 1;99(2):175-180
pubmed: 30307027
Clin Rev Allergy Immunol. 2016 Dec;51(3):263-292
pubmed: 25931325
Eur J Pain. 2016 Jan;20(1):41-6
pubmed: 26415584
Allergy Asthma Proc. 2017 Nov 1;38(6):401-408
pubmed: 29046191
Front Immunol. 2019 Jun 21;10:1303
pubmed: 31293565
Acta Microbiol Immunol Hung. 2015 Dec;62(4):341-78
pubmed: 26689873
Front Immunol. 2019 Jun 21;10:1383
pubmed: 31281316
J Immunol. 2018 Feb 15;200(4):1347-1359
pubmed: 29305434
Curr Opin Immunol. 2017 Oct;48:68-73
pubmed: 28869867
Acta Derm Venereol. 2019 Apr 1;99(5):469-506
pubmed: 30931482
Exp Dermatol. 2020 Apr;29(4):414-426
pubmed: 31954075
Curr Probl Dermatol. 2016;50:102-10
pubmed: 27578078
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36
pubmed: 29471919
Dermatology. 2017 May 10;233(1):37-46
pubmed: 28490011
Postepy Dermatol Alergol. 2013 Oct;30(5):282-5
pubmed: 24353487
Exp Dermatol. 2012 Nov;21(11):892-4
pubmed: 23163661
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
Dermatol Ther (Heidelb). 2017 Jan;7(Suppl 1):31-41
pubmed: 28150106
J Immunol. 2015 May 15;194(10):4871-9
pubmed: 25847973
Clin Exp Dermatol. 2016 Mar;41(2):183-9
pubmed: 25976154
J Immunol. 2010 Feb 1;184(3):1526-35
pubmed: 20042577
Exp Dermatol. 2019 Nov;28(11):1336-1340
pubmed: 31278779